The Solo-Founded Telehealth Wave: Why One-Person GLP-1 Brands Out-Earned $1B Incumbents in 2025
Medvi is the headline. The category is the story.
Medvi isn't alone. A wave of solo-founded cash-pay telehealth brands emerged in 2025-2026. Here is the pattern.
Timeline
Key insights
- 01Demand shape is everything. The cash-pay, recurring-prescription, broadly-advertisable categories (GLP-1, ED, hair loss, skin, sleep, mental health) are structurally well-suited to solo founders.
- 02Incumbents built scale before AI tooling collapsed the headcount requirement. Their operating cost is now a strategic disadvantage against new entrants.
- 03Outsourced clinical infrastructure is the unsexy enabler. OpenLoop and CareValidate are the 'Stripe' of telehealth for solo founders.
- 04Paid social at scale is now operable by one person with AI — creative volume, ad ops, landing page testing, and reporting all fit inside a single operator's day.
- 05Margin compression will come. Early solo entrants enjoy 15-20%+ net margins; by 2027-2028 competition and regulation will likely squeeze those to 5-10% across the category.
- 06Regulation is the real ceiling. Hims & Hers and Ro invested years in clinical governance; solo founders can match their unit economics but not their compliance depth, which is exactly where enforcement will focus.
- 07The category is a template, not an endpoint. The same operating pattern (outsourced licensed services + AI-run ops + paid social) is starting to move into legal, accounting, and financial advice — slower, because regulators are more alert, but directionally similar.
Stack used
What this means for you
- →If you are going to solo-scale in a regulated category, treat compliance as product. Build it in before you build ads.
- →Outsource the licensed parts to an orchestrator. Do not try to hire a medical director, build pharmacy relationships, and run ads in the same week.
- →Pick a category where the patient pays cash monthly. Insurance-driven businesses have entirely different unit economics and do not fit the solo pattern.
- →Expect regulators to arrive 12-18 months late. Plan the compliance stack for the day they do, not the day you launch.
- →Watch for adjacent, less-regulated categories. Skincare, sleep, supplements, and cash-pay diagnostics are smaller markets but easier first launches.
- →Understand that headcount compression is the product. The reason Medvi beats Hims on margin is not branding — it is ~1,000x fewer employees.
Frequently asked questions
Is every telehealth brand launching in 2025-2026 actually solo-founded?
No, but the pattern is surprisingly common in specific sub-segments. The clearest examples are in GLP-1 cash-pay, where a single operator can plug into a telehealth orchestrator and a pharmacy network on day one. Categories that require in-house licensed providers (complex mental health, surgery, insurance-billed primary care) still require more infrastructure and headcount. The generalization is: wherever 'licensed service as a partner' is available, solo telehealth is possible. Wherever it is not, it is not.
How can a solo founder realistically run a $400M+ telehealth business?
By not doing the work a traditional $400M telehealth business does. Solo founders do not run clinics, operate pharmacies, or employ large customer service teams. They operate a funnel: creative, ad ops, landing page, intake, and hand-off. Everything downstream is outsourced to partners who already do it at scale. Matthew Gallagher himself has publicly stated that ChatGPT, Claude, and Grok handle most of what used to be a marketing and ops department. The math works because the operator does 1-2% of the actual work of the business and collects the equity upside.
What does the FDA warning letter against Medvi mean for the category?
It means the cash-pay GLP-1 wave has matured fast enough to draw real regulatory attention. The December 2025 warning letter flagged specific claims and labeling issues (for example, text implying Medvi itself was the compounder when it is not, or marketing that equated Medvi's compounded product with Wegovy and Ozempic). For the category broadly, this signals that marketing claims, prescriber oversight, and pharmacy disclosures will be the next battleground. Solo founders who want to survive must invest in compliance as rigorously as they invest in paid acquisition.
Can this pattern move to other verticals?
It is already starting to. Cash-pay primary care concierge services, online mental-health support, cosmetic dermatology, and certain supplement and nutrition categories are seeing solo-founded experiments with similar outsourcing patterns. Outside healthcare, the closest analogs are in legal services (LLC formation, trademark filing), tax and accounting (for small businesses), and some financial advice — each with its own regulator problem. The unlock is always the same: a 'platform partner' that handles the licensed part so the operator can focus on funnel and funding.
What would a Series A-backed competitor do to stop a solo Medvi-style brand?
Three things, if they were competent. First, aggressively defend brand search and review sites so that a Medvi-like newcomer cannot hijack their traffic. Second, ship faster cross-channel creative — the solo brands are winning on creative volume, and funded teams can technically match or exceed that with the right structure. Third, work with regulators proactively to establish clinical governance standards that small operators cannot meet. Hims and Ro are attempting versions of all three; the outcome over the next 18 months will determine whether the category stays solo-operable at scale.
Related resources
Medvi: $20K to $401M in 12 Months | Case Study
Matthew Gallagher built Medvi from a $20K check to $401M revenue in its first year with AI. Here is exactly how.
Polsia: $0 to $3.5M ARR in 90 Days | Case Study
Ben Broca launched Polsia Dec 2025. 4,000 autonomous companies, $3.5M ARR, zero human employees. Here is the full breakdown.
Pieter Levels: $3M/yr Solo, 0 Employees | Case Study
Pieter Levels built 70+ projects, 3 of them past $38K MRR each, solo since 2014. The original one-person company playbook.
The One-Person Billion-Dollar Company Playbook (2026)
Sam Altman predicted it. Matthew Gallagher proved it with Medvi's $1.8B projected 2026. Here's the playbook — market, stack, execution, milestones.
Reach $1M ARR Solo: The Playbook (2026)
The systematic path from $0 to $1M ARR as a solo founder in 2026. Category picks, stack, milestones, numbers that actually work.
One-Person Company: Run a Solo Business With AI (2026)
A one-person company is a business run by a single founder with AI employees handling execution. The playbook — roles, stack, economics, examples.
Run your one-person company.
Hire your AI team in 30 seconds. Start for free.
Free to start · No credit card required · Set up in 30 seconds